News articles about Innoviva (NASDAQ:INVA) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innoviva earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.9556499399922 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Forecasting Future Earnings Review: Innoviva, Inc.’s (INVA) (getstocksnews.com)
- Technical gives deep insight into Innoviva, Inc. (INVA) (wallstreetmorning.com)
- Stock Performance Summary: Innoviva, Inc. (INVA) (mostvolatilestocks.com)
- Oscillating Stocks: Qorvo, Inc. (NASDAQ:QRVO), Marathon Petroleum Corporation (NYSE:MPC), Innoviva, Inc … (journalfinance.net)
- Here is Risky Stock That May Deliver higher returns:: Innoviva, Inc. (INVA) (wallstreetinvestorplace.com)
NASDAQ:INVA opened at $16.14 on Friday. The company has a current ratio of 5.77, a quick ratio of 5.77 and a debt-to-equity ratio of -2.37. The company has a market capitalization of $1,643.44, a P/E ratio of 13.91 and a beta of 2.17. Innoviva has a 12 month low of $11.02 and a 12 month high of $17.99.
A number of equities research analysts recently issued reports on INVA shares. BidaskClub raised Innoviva from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 24th. Zacks Investment Research downgraded Innoviva from a “hold” rating to a “sell” rating in a report on Tuesday, February 20th. TheStreet raised Innoviva from a “c+” rating to a “b” rating in a report on Friday, February 9th. ValuEngine raised Innoviva from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $17.00 target price on shares of Innoviva in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $14.17.
In other Innoviva news, VP George B. Abercrombie sold 8,000 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $16.51, for a total transaction of $132,080.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Desparbes sold 5,378 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $16.52, for a total transaction of $88,844.56. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Innoviva (INVA) Earning Somewhat Positive News Coverage, Study Shows” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://weekherald.com/2018/04/22/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-innoviva-inva-stock-price.html.
Innoviva Company Profile
Innoviva, Inc engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.